Hanall Biopharma Co (XKRX:009420) Other Net Income (Loss)

: ₩-0 Mil (TTM As of Dec. 2023)

View and export this data going back to 1989. Start your Free Trial

Hanall Biopharma Co's Other Net Income (Loss) for the three months ended in Dec. 2023 was ₩-0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-0 Mil.

Hanall Biopharma Co's quarterly Other Net Income (Loss) stayed the same from Jun. 2023 (₩0 Mil) to Sep. 2023 (₩0 Mil) but then declined from Sep. 2023 (₩0 Mil) to Dec. 2023 (₩-0 Mil).

Hanall Biopharma Co's annual Other Net Income (Loss) declined from Dec. 2021 (₩0 Mil) to Dec. 2022 (₩-0 Mil) but then increased from Dec. 2022 (₩-0 Mil) to Dec. 2023 (₩0 Mil).

Hanall Biopharma Co Other Net Income (Loss) Historical Data

The historical data trend for Hanall Biopharma Co's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => - [6] => - [7] => - [8] => - [9] => - )

Hanall Biopharma Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Hanall Biopharma Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Net Income (Loss)																-	-	-	-	-

Hanall Biopharma Co Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-0 Mil.

Hanall Biopharma Co Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Hanall Biopharma Co's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Hanall Biopharma Co (XKRX:009420) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hanall Biopharma Co Ltd (XKRX:009420) » Definitions » Other Net Income (Loss)

Traded in Other Exchanges

N/A

Address

12 Bongeunsa-ro 114-gil, Daewoong Building, 3rd Floor, Gangnam-gu, Seoul, KOR

Website

http://www.hanall.co.kr

Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.

Hanall Biopharma Co (XKRX:009420) Headlines

No Headlines